Galafold 123 MG
Ended Awarded
- Contract number
- 36C24526N0158
- Awardee
-
Amicus Therapeutics US, LLC UEI KLJFGENKMD89
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $21,891
Award facts
- Contract value 100% obligated
- $21,891.21 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order valued at $21,891.21 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg on November 20, 2025, with an ultimate completion date of November 25, 2025. This firm fixed-price delivery order, with no set-aside designation, represents a task order placed under Amicus Therapeutics' existing Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The pharmaceutical will be delivered to Philadelphia, Pennsylvania and supports the VA's mission to provide specialized healthcare services to veterans.
Galafold (migalastat) is an enzyme replacement therapy used in the treatment of Fabry disease, a rare genetic disorder. Amicus Therapeutics US, LLC, a biopharmaceutical company specializing in treatments for rare genetic diseases, has established itself as a key supplier of this specialized medication to the VA through multiple delivery orders across various VISN regions. The company maintains a master FSS contract valued at $13,024,630 through August 31, 2029, which enables VA healthcare facilities nationwide to efficiently procure this critical pharmaceutical product for treating eligible veterans with Fabry disease.
Quick answers
Who was awarded contract 36C24526N0158?
36C24526N0158 was awarded to Amicus Therapeutics US, LLC by Veterans Integrated Service Network 5 (Veterans Health Administration) on November 20, 2025.
How much is contract 36C24526N0158 worth?
The government has obligated $21,891 on 36C24526N0158.
Is contract 36C24526N0158 an order under another contract?
Yes. 36C24526N0158 is a delivery order under 36F79724D0185, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0158 competed?
The extent of competition for 36C24526N0158 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award